A New Approach to Antiplatelet Therapy: Inhibitor of GPIb/V/IX-vWF Interaction

Publisher： Karger

E-ISSN： 1424-8840|30|3|44-52

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.30, Iss.3, 2004-11, pp. : 44-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drospirenone enhances GPIb‐IX‐V‐mediated platelet activation

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 1538-7933, Iss. 10, 2015-10 ,pp. : 1918-1924

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Diversity in Clinical Presentation of Acquired Factor V Inhibitor

By  

Acta Haematologica, Vol. 119, Iss. 2, 2008-03 ,pp. : 108-110

Karger

Access to resources Recommend Favorite

Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems

By Horiuchi Hisanori  

Annals of Medicine, Vol. 38, Iss. 3, 2006-05 ,pp. : 162-172

Informa Healthcare

Access to resources Recommend Favorite

Further Characterization of Anti-Platelet Monoclonal Antibody HPL5 as Anti-Glycoprotein V Antibody

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 128-130

Karger

Access to resources Recommend Favorite

Switching to low dose of plasma‐derived factor VIII/vWF concentrates with Confact®‐F as salvage immune tolerance induction in haemophilia A patients with inhibitors: five case reports from Japan

By  

HAEMOPHILIA, Vol. 1351-8216, Iss. 5, 2015-09 ,pp. : e425-e427

John Wiley & Sons Inc

Access to resources Recommend Favorite